Tango Therapeutics TNGX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Business | ||||||
| Discovery Direct Program Expenses-RD | $7.36M-68.8% | $10.17M-58.4% | $13.41M-48.0% | $18.8M-24.0% | $23.61M+2.3% | |
| Facilities And Other Related Expenses-RD | $19.34M-0.7% | $20.46M+8.4% | $19.34M-1.9% | $19.49M+2.2% | $19.47M+7.9% | |
| Personnel-Related Expenses-RD | $50.56M-3.7% | $51.47M0.0% | $52.21M+8.9% | $52.24M+15.7% | $52.51M+26.1% | |
| TNG260Direct Program Expenses-RD | $6.56M-26.1% | $6.28M-33.1% | $6.64M-33.5% | $6.92M-31.4% | $8.88M+6.1% | |
| TNG456Direct Program Expenses-RD | $7.3M+24.6% | $6.56M+44.7% | $9.5M— | $7.5M— | $5.86M— | |
| TNG908Direct Program Expenses-RD | $3.9M-64.7% | $5.03M-63.0% | $6.99M-48.2% | $9.02M-30.3% | $11.04M-10.9% | |
| TNG961Direct Program Expenses-RD | $3.86M+73.9% | $5.68M— | $4.86M— | $3.79M— | $2.22M— | |
| Vopimetostat Direct Program Expenses-RD | $30.39M— | $26.52M— | $21.11M— | $18.16M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Tango Therapeutics break its business down?
- Tango Therapeutics (TNGX) reports research and development expense by business across 8 parts — Discovery Direct Program Expenses-RD, Facilities And Other Related Expenses-RD, Personnel-Related Expenses-RD, TNG260Direct Program Expenses-RD and TNG456Direct Program Expenses-RD. Each is extracted from the segment footnotes and tracked over time.
- Where does Tango Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Tango Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.